- BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
- BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- BioLineRx to Report First Quarter 2024 Results on May 28, 2024
- BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
- BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
- BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
More ▼
Key statistics
As of last trade, Bioline Rx Ltd (BLRX:TLV) traded at 17.60, 19.73% above the 52 week low of 14.70 set on Jul 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.50 |
---|---|
High | 17.80 |
Low | 17.50 |
Bid | 17.60 |
Offer | 17.70 |
Previous close | 17.30 |
Average volume | 617.76k |
---|---|
Shares outstanding | 1.20bn |
Free float | 1.20bn |
P/E (TTM) | -- |
Market cap | 208.43m ILS |
EPS (TTM) | -0.184 ILS |
Data delayed at least 20 minutes, as of Jul 16 2024 10:06 BST.
More ▼